



**University of  
Zurich**<sup>UZH</sup>

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2005

---

## **ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC)**

Felip, E ; Pavlidis, N ; Stahel, R A

DOI: <https://doi.org/10.1093/annonc/mdi829>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-154716>

Journal Article

Published Version

Originally published at:

Felip, E; Pavlidis, N; Stahel, R A (2005). ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). *Annals of Oncology*, 16(suppl<sub>1</sub>) : i30 – i31.

DOI: <https://doi.org/10.1093/annonc/mdi829>

# ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC)

## Incidence

- The crude incidence of lung cancer in the European Union is 52.5/100 000 per year, the mortality 48.7/100 000 per year. Among men the rates are 82.5 and 77.0/100 000 per year, among women 23.9 and 22.3/100 000 per year, respectively. SCLC accounts for 20% of all cases. About 90% of lung cancer mortality among men (and 80% among women) is attributable to smoking.

## Diagnosis

- Pathological diagnosis should be made according to the World Health Organisation classification from a bronchoscopic, Tru-cut or surgical biopsy or fine needle aspiration.

## Staging and risk assessment

- Patients are usually staged according to a simple two-stage system developed by the Veteran's Administration Lung Cancer Study Group as limited disease (LD) or extensive disease (ED):

### Limited disease

- The definition is based on the possibility of encompassing all detectable tumor within a "tolerable" radiotherapy port. Patients with limited disease have tumor deposits restricted to one hemithorax with regional lymph node metastasis including ipsilateral hilar, ipsilateral supraclavicular, mediastinal and contralateral hilar nodes.

### Extensive disease

- It represents any tumor beyond the bounds defined above including ipsilateral lung metastases and malignant pleural effusion.
- In addition to a complete history and physical examination, staging procedures should at least include the following: chest X-ray, complete blood count, liver and renal function tests, LDH, sodium, and a CT scan of chest and upper abdomen.
- Additional tests to define limited disease in patients with symptoms or abnormal physical examination suggesting metastasis are: a bone scintigraphy, a CT scan or MRI of the brain, and a bone marrow biopsy. Once any one of these tests is positive, extensive disease has been confirmed and there is no need to proceed with the rest of the tests [V, D].

## Treatment

### Treatment of limited disease

- Standard regimens, also for patients diagnosed at surgery, are either based on etoposide-platinum or cyclophosphamide-doxorubicin and should be given for 4–6 cycles [I, A]. Maintenance chemotherapy does not result in any substantial improvement in survival [II, A].
- Etoposide-cisplatin is widely regarded as state-of-the-art chemotherapy for limited disease, particularly because this regimen can be combined with concurrent irradiation without unacceptable toxicity [II, A].
- Chest radiotherapy increases local control and survival and should be given to all patients with limited disease. Several studies suggest to start thoracic radiotherapy early during chemotherapy [II–III, A].
- Prophylactic cranial irradiation is indicated in patients with a complete remission from limited disease because it reduces the lifetime risk of cerebral metastases and improves survival [II, B].

### Treatment of extensive disease

- Chemotherapy with the same regimens as for limited disease and given for 4–6 cycles also improves survival for patients with extensive disease and is usually the most effective way to ameliorate clinical symptoms [II, A].

### Second-line chemotherapy

- Patients relapsed from a response to first-line chemotherapy should be considered for second-line chemotherapy [III, B].

## Response evaluation

- Response evaluation is recommended at least at the end of treatment by repetition of the initial radiographic tests [V, D].

## Follow-up

- There is no evidence that follow-up of asymptomatic patients is needed. Specific examinations as clinically indicated.

## Note

Levels of Evidence [I–V] and Grades of Recommendation [A–D] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were

considered justified standard clinical practice by the experts and the ESMO faculty.

## Literature

1. Sundstrom S, Bremnes RM, Kaasas S et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. *J Clin Oncol* 2002; 20: 4665–4672.
2. Pignon JP, Arriagada R, Ihde DC et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. *N Engl J Med* 1992; 327: 1618–1624.
3. McCracken JD, Janaki LM, Crowley JJ et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group Study. *J Clin Oncol* 1990; 8: 892–898.
4. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. *N Engl J Med* 1999; 341: 476–484.

Coordinating authors for the ESMO Guidelines Task Force: E. Felip<sup>1</sup>, N. Pavlidis<sup>2</sup> & R. A. Stahel<sup>3</sup>

<sup>1</sup>Invited author, Hospital Universitario Vall D'Hebron, Barcelona, Spain;

<sup>2</sup>Assigned task force member, University of Ioannina, Dept. Medical Oncology, 45110 Ioannina, Greece; <sup>3</sup>Assigned task force member, Div. of Oncology, University Hospital, Rämistr. 100, CH-8091 Zürich, Switzerland

Approved by the ESMO Guidelines Task Force: February 2002, last update December 2004.

*Correspondence to:*

ESMO Guidelines Task Force  
ESMO Head Office  
Via La Santa 7  
CH-6962 Lugano  
Switzerland